We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

SAP:XETRSAP SE Analysis

Data as of 2026-03-09 - not real-time

$200.68

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

SAP shares are trading at $200.68, just below the 20‑day SMA of $201.55 and well under the 50‑day SMA of $218.67, indicating short‑term pressure. The RSI sits at 44.6, suggesting neutral momentum, while the MACD histogram turned positive (+1.36) signaling a potential near‑term bounce. Volatility is elevated at 60 % over the past 30 days, and the beta of 0.82 points to moderate market sensitivity. Support at $187.94 and resistance near $212.98 frame the current trading range.
Fundamentally, SAP delivers a robust 73.8 % gross margin and a healthy 29 % operating margin, with revenue growing 3.3 % YoY. The forward PE of 20× is well below the industry average of 36.7×, and the dividend yield of 1.47 % is backed by a 38 % payout ratio and strong cash generation (≈$9.5 B cash vs $7.5 B debt). The recent AI‑first partnership with KPMG adds a strategic growth catalyst. Overall, the stock appears fairly priced relative to peers but modestly overvalued against its own DCF estimate, leaving upside potential toward analyst targets around $300.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price hovering just below the 20‑day SMA suggests limited upside
  • Positive MACD histogram indicates a possible short‑term bounce
  • High 30‑day volatility and bearish trend direction increase uncertainty

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Forward PE of 20× is well under the industry average of 36.7×
  • Strong operating margins and cash flow support earnings growth
  • Analyst target median price of $304 implies >50% upside

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Strategic AI‑first alliance with KPMG expands future growth opportunities
  • Sustainable dividend payout with low payout ratio and solid balance sheet
  • Stable revenue growth and high gross margin underpin long‑term profitability

Key Metrics & Analysis

Financial Health

Revenue Growth3.30%
Profit Margin19.46%
P/E Ratio28.3
ROE16.12%
ROA9.01%
Debt/Equity16.59
P/B Ratio4.5
Op. Cash Flow$9.2B
Free Cash Flow$8.5B
Industry P/E36.7

Technical Analysis

TrendBearish
RSI44.6
Support$187.94
Resistance$212.98
MA 20$201.55
MA 50$218.67
MA 200$260.48
MACDBullish
VolumeIncreasing
Fear & Greed Index100

Valuation

Fair Value$118.06
Target Price$299.50
Upside/Downside49.25%
GradeFair
TypeBlend
Dividend Yield1.47%

Risk Assessment

Beta0.82
Volatility60.07%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.